Schrödinger (SDGR) Competitors

Sage Therapeutics (NASDAQ:SAGE) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Do insiders and institutionals hold more shares of SAGE or SDGR?

99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts prefer SAGE or SDGR?

Sage Therapeutics presently has a consensus target price of $35.05, suggesting a potential upside of 215.48%. Schrödinger has a consensus target price of $42.80, suggesting a potential upside of 98.88%. Given Schrödinger's higher possible upside, research analysts clearly believe Sage Therapeutics is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	2 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.05
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is SAGE or SDGR more profitable?

Schrödinger has a net margin of -75.94% compared to Schrödinger's net margin of -552.52%. Sage Therapeutics' return on equity of -29.25% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-552.52%	-56.81%	-51.01%
Schrödinger	-75.94%	-29.25%	-20.60%

Which has more risk and volatility, SAGE or SDGR?

Sage Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Does the media refer more to SAGE or SDGR?

In the previous week, Sage Therapeutics had 13 more articles in the media than Schrödinger. MarketBeat recorded 16 mentions for Sage Therapeutics and 3 mentions for Schrödinger. Sage Therapeutics' average media sentiment score of 1.66 beat Schrödinger's score of 0.57 indicating that Schrödinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sage Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrödinger	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has better valuation & earnings, SAGE or SDGR?

Schrödinger has higher revenue and earnings than Sage Therapeutics. Schrödinger is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$86.46M	7.73	-$541.49M	-$8.40	-1.32
Schrödinger	$216.67M	7.22	$40.72M	-$1.88	-11.45

Does the MarketBeat Community believe in SAGE or SDGR?

Sage Therapeutics received 578 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 67.60% of users gave Sage Therapeutics an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Sage Therapeutics	Outperform Votes 626 67.60%	Underperform Votes 300 32.40%
Schrödinger	Outperform Votes 48 55.17%	Underperform Votes 39 44.83%

Summary

Schrödinger beats Sage Therapeutics on 11 of the 18 factors compared between the two stocks.